Literature DB >> 3700468

Bacterial lipopolysaccharide suppresses the production of catalytically active lysosomal acid hydrolases in human macrophages.

D W Riches, P M Henson.   

Abstract

Sub-microgram quantities of bacterial lipopolysaccharide (LPS) have been found to substantially reduce the intracellular catalytic activities of three representative lysosomal enzymes (namely, acid phosphatase, hexosaminidase, and beta-glucuronidase) in human monocyte-derived macrophages. This response was not associated with a concurrent increase in enzyme catalytic activity in the culture supernatant, and hence, could not be explained by mobilization of preformed material. By conducting experiments in the presence and absence of indomethacin, a cyclooxygenase inhibitor, the reduction in lysosomal enzyme catalytic activities was shown not to be dependent on the ability of LPS to induce prostaglandin E2 production. The response was not found to be the result of a more generalized LPS-dependent reduction in the ability of the cells to synthesize protein, since the presence of LPS in macrophage cultures did not appreciably affect the amount of [35S]methionine incorporated into total cellular proteins. A kinetic analysis of the effect of LPS on the down-regulation of enzyme catalytic activities indicated that this was an early response of the cells to LPS exposure. An investigation of the effects of blockade of enzyme catabolism (using the lysosomotropic weak-base, methylamine) indicated that the reduction of catalytic enzyme activities in response to LPS was probably due to a decreased rate of production of active product, rather than an enhanced rate of enzyme catabolism. This suggestion was confirmed by experiments in which the synthesis of pro-hexosaminidase (measured by biosynthetic labeling with [35S]methionine and specific immunoprecipitation of labeled pro-hexosaminidase) was found to be reduced by 42% after a 24-h exposure to LPS (although the synthesis of complement component C3 was stimulated by a factor of 4.5). It is suggested that the ability of LPS to regulate the functional expression of protein products contributes to changes in the overall functional status of these cells in response to this bacterial product.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700468      PMCID: PMC2114209          DOI: 10.1083/jcb.102.5.1606

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  36 in total

1.  The endotoxin-induced coagulant activity of human monocytes.

Authors:  R P Rivers; W E Hathaway; W L Weston
Journal:  Br J Haematol       Date:  1975-07       Impact factor: 6.998

2.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.

Authors:  S Ohkuma; B Poole
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

3.  Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin.

Authors:  P O Seglen; B Grinde; A E Solheim
Journal:  Eur J Biochem       Date:  1979-04-02

4.  Collagenase production by endotoxin-activated macrophages.

Authors:  L M Wahl; S M Wahl; S E Mergenhagen; G R Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

5.  Humoral and formed elements of blood modulate the response of peripheral blood monocytes. I. Plasma and serum inhibit and platelets enhance monocyte adherence.

Authors:  R A Musson; P M Henson
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Endotoxin and double stranded RNA render macrophages cytotoxic.

Authors:  P Alexander; R Evans
Journal:  Nat New Biol       Date:  1971-07-21

8.  Are double-stranded RNA-directed inhibition of protein synthesis in interferon-treated cells and interferon induction related phenomena?

Authors:  P F Torrence; R M Friedman
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

9.  Macrophage stimulation by bacterial lipopolysaccharides. I. Cytolytic effect on tumor target cells.

Authors:  W F Doe; P M Henson
Journal:  J Exp Med       Date:  1978-08-01       Impact factor: 14.307

10.  Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages.

Authors:  J I Kurland; R Bockman
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  5 in total

1.  Transmembrane-mediated changes in [Ca2+] are involved in the signaling pathway leading to macrophage cytocidal differentiation: implications of localized changes in intracellular [Ca2+] and of interferon priming on Ca2+ utilization.

Authors:  G A Underwood; D W Riches
Journal:  Mol Biol Cell       Date:  1992-03       Impact factor: 4.138

2.  A membrane vesicle/ribosome preparation from Serratia marcescens elicits peritoneal exudate cells expressing both tumoricidal and bactericidal activity.

Authors:  C McCall; L Weimer; S Baldwin; D W Riches; B Canono; P A Campbell
Journal:  Inflammation       Date:  1992-08       Impact factor: 4.092

3.  Development of functional diversity in mouse macrophages. Mutual exclusion of two phenotypic states.

Authors:  D J Laszlo; P M Henson; L K Remigio; L Weinstein; C Sable; P W Noble; D W Riches
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

4.  Functional switching of macrophage responses to tumor necrosis factor-alpha (TNF alpha) by interferons. Implications for the pleiotropic activities of TNF alpha.

Authors:  F R Lake; P W Noble; P M Henson; D W Riches
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

5.  Bafilomycin A1 enhances NLRP3 inflammasome activation in human monocytes independent of lysosomal acidification.

Authors:  Shi Yu; Jack Green; Rose Wellens; Gloria Lopez-Castejon; David Brough
Journal:  FEBS J       Date:  2020-11-21       Impact factor: 5.542

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.